UP!

News

Cytokinetics, Incorporated 0.96% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-01 Future report Set alerts
Q3 2020 2020-10-29 Future report Set alerts
Q2 2020 2020-08-06 -0.68 -0.68
Q1 2020 2020-05-06 -0.66 -0.66
Q4 2019 2020-03-03 -0.52 -0.52
Q3 2019 2019-10-31 -0.50 -0.50
Q2 2019 2019-08-08 -0.56 -0.56
Q1 2019 2019-05-09 -0.54 -0.54
Q4 2018 2019-02-21 -0.48 -0.48
Q3 2018 2018-11-01 -0.40 -0.40

Ratings

2016-06-21 Reiterated Rating FBR & Co. Buy $24.00
2016-06-21 Reiterated Rating FBR & Co Buy $24.00
2016-05-25 Reiterated Rating Piper Jaffray Overweight $24.00
2016-05-25 Reiterated Rating Piper Jaffray Cos. Overweight $24.00
2016-05-02 Reiterated Rating FBR & Co. Buy
2016-04-30 Reiterated Rating Roth Capital Buy
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $16.00 to $14.00
2016-03-09 Lower Price Target JMP Securities Market Outperform $16.00 to $14.00
2016-02-23 Reiterated Rating Roth Capital Buy $22.00
2016-02-17 Reiterated Rating Cowen and Company Buy $16.00
2016-01-20 Reiterated Rating Roth Capital Buy $22.00
2016-01-05 Reiterated Rating Piper Jaffray Overweight $24.00
2015-12-16 Reiterated Rating Piper Jaffray Buy $17.00 to $24.00
2015-11-10 Boost Price Target FBR & Co. Outperform $14.00 to $24.00
2015-11-09 Boost Price Target Roth Capital Buy $18.00 to $22.00
2015-10-23 Reiterated Rating Roth Capital Buy $18.00
2015-09-15 Reiterated Rating FBR & Co. Outperform $14.00
2015-07-31 Reiterated Rating Roth Capital Buy $18.00
2015-07-24 Reiterated Rating MLV & Co. Buy $9.00 to $14.00
2015-07-15 Reiterated Rating Roth Capital Buy $18.00
2015-07-15 Initiated Coverage Cowen and Company Outperform $9.00
2015-05-01 Reiterated Rating MLV & Co. Buy $9.00
2015-02-13 Upgrade Piper Jaffray Neutral to Overweight $13.00
2015-01-26 Set Price Target Roth Capital Buy $18.00
2014-12-31 Boost Price Target Roth Capital Buy $13.00 to $18.00
2014-11-04 Upgrade MLV & Co Hold to Buy $9
2014-11-04 Upgrade MLV & Co. Hold to Buy $5.00 to $9.00
2014-10-20 Reiterated Rating Roth Capital Buy
2014-07-10 Reiterated Rating Roth Capital Buy
2014-05-19 Reiterated Rating Leerink Swann Outperform $20.00 to $8.00
2014-05-08 Reiterated Rating Canaccord Genuity Buy $9.00 to $8.00
2014-04-28 Reiterated Rating Canaccord Genuity Buy $22.00 to $9.00
2014-04-28 Lower Price Target Needham & Company LLC Buy $25.00 to $15.00
2014-04-25 Downgrade MLV & Co. Buy to Hold $26.00 to $5.00
2014-04-25 Downgrade Piper Jaffray Overweight to Neutral $18.00 to $7.00
2014-03-05 Initiated Coverage Roth Capital Buy $25.00
2014-02-21 Lower Price Target Piper Jaffray $24.00 to $18.00
2013-10-11 Reiterated Rating Needham & Company LLC Buy
2013-06-26 Reiterated MLV & Co Buy $24 to $26
2012-07-02 Initiated Needham Buy $2.50
2009-10-29 Downgrade Needham Buy to Hold
2009-09-21 Reiterated Wedbush Morgan Outperform $4 to $18
2008-03-19 Reiterated Cantor Fitzgerald Buy $19 to $16
2007-07-19 Initiated Credit Suisse Outperform $11
2007-02-01 Reiterated Cantor Fitzgerald Buy $8 to $19
2007-01-03 Reiterated Rodman & Renshaw Mkt Outperform $10 to $12
2007-01-03 Reiterated RBC Capital Mkts Sector Perform $8 to $10
2016-06-21 Reiterated Rating FBR & Co. Buy $24.00
2016-06-21 Reiterated Rating FBR & Co Buy $24.00
2016-05-25 Reiterated Rating Piper Jaffray Overweight $24.00
2016-05-25 Reiterated Rating Piper Jaffray Cos. Overweight $24.00
2016-05-02 Reiterated Rating FBR & Co. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SCHMERTZLER MICHAEL 11.86%  (4340923) CYTK / PTCT /
Eastern Capital LTD 7.88%  (2883845) ASTM / CYCC / CYTK / IBIO / PPHM /
DOW STEPHEN M 3.88%  (1421052) ALDR / CTXS / CYTK /
Blum Robert I President & CEO 0.49%  (180022) CYTK /
Malik Fady Ibraham SVP Research & Early Dev 0.27%  (98072) CYTK /
Cragg David SVP Human Resources 0.23%  (85865) CYTK /
WOLFF ANDREW A SVP Clinical R&D, CMO 0.13%  (47255) CYTK /
Morgan Bradley Paul SVP Drug Discovery & Early Dev 0.13%  (46441) CYTK /
Schnieders Elisabeth Sr. VP, Business Development 0.12%  (43919) CYTK /
BARBARI SHARON SURREY EVP, Finance & CFO 0.11%  (40323) CYTK / OCLS /
GAGE L PATRICK 0.10%  (35000) CYTK / PDLI / TTPH /
McDowell Caryn Gordon GC & Chief Compliance Officer 0.09%  (32548) CYTK / RVNC /
CHARPENTIER BONNIE SVP Regulatory & Compliance 0.08%  (29004) CYTK /
RODDY PETER S SVP Finance & CAO 0.06%  (21520) CYTK / PTIE / VRML /
Jaw Ching SVP Finance & CFO 0.05%  (20000) CYTK /

Comments